Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Veltuzumab (hA20) in CD20+ Non-Hodgkin's Lymphoma
NCT00285428Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2004
- Primary completion
- Oct 2007
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of veltuzumab in non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Safety and tolerance of different dose levels at 12 weeks. Started Sep 2004; status: completed.
02
Drugs
veltuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00285428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00285428.